Illumina Files Registration Statement Over Potential Divestiture Of Grail

Reuters (12/11, Mishra) reports, “Illumina said on Monday it had filed a registration statement with the U.S. securities regulator related to a potential divestiture of Grail, even as it challenges a European Union order to divest the cancer test maker in court.” In October, Illumina “said it would divest Grail in 12 months, according to the terms of the European Commission’s order, if the life sciences company does not win its challenge in court.”